A Long-Term Spinal Intramedullary Response to Ceritinib in ALK Rearranged Non-Small-Cell Lung Cancer

J Thorac Oncol. 2015 Jun;10(6):e44-5. doi: 10.1097/JTO.0000000000000501.

Abstract

With advanced non-small-cell lung cancer (NSCLC) harboring, the anaplastic lymphoma kinase (ALK) gene rearrangement often responds impressively to ALK inhibitors, such as crizotinib. Acquired tumor resistance to ALK inhibition develops after a median progression-free survival of 7.7 to 10.9 months, with several mechanisms of resistance already described. Second generation ALK inhibitors, such as ceritinib, may overcome some of these mechanisms and have known efficacy in brain metastases. Their effect on intramedullary spinal cord metastases, a rare form of central nervous system metastases, is unknown.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Anaplastic Lymphoma Kinase
  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / enzymology
  • Carcinoma, Non-Small-Cell Lung / genetics*
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Gene Rearrangement
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / enzymology
  • Lung Neoplasms / genetics*
  • Lung Neoplasms / pathology
  • Male
  • Protein Kinase Inhibitors / therapeutic use*
  • Pyrimidines / therapeutic use*
  • Receptor Protein-Tyrosine Kinases / genetics*
  • Sulfones / therapeutic use*

Substances

  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Sulfones
  • ALK protein, human
  • Anaplastic Lymphoma Kinase
  • Receptor Protein-Tyrosine Kinases
  • ceritinib